<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; content</title>
	<atom:link href="http://www.tapanray.in/tag/content/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>This New Engagement Model Garners Significant Rewards For Pharma</title>
		<link>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=this-new-engagement-model-garners-significant-rewards-for-pharma</link>
		<comments>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/#comments</comments>
		<pubDate>Mon, 28 Nov 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[cyberspace]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[difference]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10731</guid>
		<description><![CDATA[Last year, on July 26, 2021, I wrote in this blog on gaining a competitive edge with Omnichannel pharma marketing Omnichannel pharma marketing. However, from several recent studies, it appears, it’s still remains in a nascent stage. Most players in the industry haven’t &#8230; <a href="http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Augment Pharma Customers’ New Value Expectations With Content Marketing</title>
		<link>http://www.tapanray.in/augment-pharma-customers-new-value-expectations-with-content-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=augment-pharma-customers-new-value-expectations-with-content-marketing</link>
		<comments>http://www.tapanray.in/augment-pharma-customers-new-value-expectations-with-content-marketing/#comments</comments>
		<pubDate>Mon, 31 May 2021 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[augment]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[value expectation]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10518</guid>
		<description><![CDATA[‘COVID-19 is driving lasting changes in what HCPs need and value,’ found the Accenture Healthcare Provider Survey May 2020, named – ‘Reinventing Relevance.’ Several physicians from the US, Europe and Asia were found to have experienced a significant change taking place in &#8230; <a href="http://www.tapanray.in/augment-pharma-customers-new-value-expectations-with-content-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/augment-pharma-customers-new-value-expectations-with-content-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time To Audit Pharma’s Doctor-Engagement And Other Digital Strategies</title>
		<link>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies</link>
		<comments>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/#comments</comments>
		<pubDate>Mon, 25 Jan 2021 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[audit]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[e-visits]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[format]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value-delivery]]></category>
		<category><![CDATA[walk the talk]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10400</guid>
		<description><![CDATA[It’s now over a year since the unprecedented global health crisis commenced. In this grueling saga, a silver lining is also visible. It helped pharma industry gain a fascinating operational experience, while navigating through disruptive business changes. The changes in the &#8230; <a href="http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should Pharma-Doctor Communication Be Also Gender-Specific?</title>
		<link>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-doctor-communication-be-also-gender-specific</link>
		<comments>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/#comments</comments>
		<pubDate>Mon, 26 Nov 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[choosing]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[concordance]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[Gender]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[internists]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9268</guid>
		<description><![CDATA[Regardless of situations, while selecting a suitable doctor for patients, or for that matter, pharma companies engage with them for commercial reasons, their gender doesn’t matter much to many. What one generally looks for is, whether they are General Practitioners &#8230; <a href="http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Relevance of Content Marketing In Pharma</title>
		<link>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-relevance-of-content-marketing-in-pharma</link>
		<comments>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/#comments</comments>
		<pubDate>Sun, 11 Jun 2017 23:49:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UDFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8268</guid>
		<description><![CDATA[“Nearly half of pharma industry may come under price control” – was the headline of a media report of June 7, 2017. Although, National Pharmaceutical Pricing Authority (NPPA) has apparently denied any such move, the fact is that the number &#8230; <a href="http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
